A simple equation provides real-time feedback to detect access recirculation in arteriovenous fistulas (AVFs) during hemodialysis, reports a study in the September/October issue of ASAIO Journal, Official Journal of the American Society of Artificial Internal Organs. The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health, a leading provider of information and business intelligence for students, professionals, and institutions in medicine, nursing, allied health, pharmacy and the pharmaceutical industry.
Arteriovenous fistulas have become the preferred form of vascular access in chronic hemodialysis patients, as they make dialysis safer and easier for patients. However, problems related to fistula stenoses (narrowing) can develop over time. Early detection and correction of stenoses can help to prevent inadequate dialysis and other complications.
Dividing the effective ionic dialysance (EID) by the blood flow rate (Qb) to calculate the “EID/Qb ratio” provides an accurate tool to screen for the problem of recirculation in AVFs used for dialysis access, according to the new study.
Other techniques proposed to detect access recirculation as an indicator of AVF function have been impractical for routine use. “Obtaining this ratio is potentially simple, noninvasive, and uses widely available standard equipment with no additional cost,” write Dr. Sumit Mohan and colleagues of Columbia University College of Physicians and Surgeons, New York.
Automatically Calculated Ratio Detects Problems with AVF Function
Access recirculation occurring in the AVF is a sign of fistula stenosis or other causes of inadequate flow rates. Particularly at the high flow rates used in modern high-efficiency hemodialysis systems, some convenient and accessible means of detecting access recirculation is needed.
Dr. Mohan and colleagues designed a study to evaluate the use of the EID/Qb ratio, automatically calculated by the dialysis system during treatment, as an indicator of access recirculation problems. The study included 47 dialysis patients with AVFs. In a total of 323 hemodialysis sessions, the standard saline dilution technique detected access recirculation in 17 cases—a rate of 5.3 percent.
The EID/Qb ratio performed well in detecting access recirculation. At a value of 50 percent or less, the EID/Qb ratio correctly identified 76.5 percent of patients with access recirculation (sensitivity), while ruling out access recirculation in 96.4 percent of patients who did not have it (specificity).
In two cases, access recirculation was caused by inadvertent reversal of the hemodialysis blood lines—these were also detected by the EID/Qb ratio. The ratio performed similarly well when dialysis was performed using a high-efficiency dialysis machine and on a slower flow-rate machine.
The EID is a relatively new measure of dialysis dose, depending partly on the blood flow rate. The EID/Qb ratio can be easily and continuously calculated by the dialysis equipment, providing real-time feedback on AVF function.
The new study suggests that the EID/Qb ratio is a useful technique for routine monitoring of AVF function during dialysis sessions. It offers good accuracy in identifying patients with possible AVF problems in need of further evaluation. It also appears useful in monitoring for technical problems such as line reversal or needle malposition. “The EID/Qb ratio is an excellent online chairside test for identifying access recirculation during hemodialysis in patients with AVF,” Dr. Mohan and colleagues conclude.
About ASAIO Journal
ASAIO Journal, official journal of the American Society of Artificial Internal Organs, is in the forefront of artificial organ research and development. On the cutting edge of an exploding technology, it features peer-reviewed articles of the highest quality that describe the research, development and application of biomaterials, the most recent advances in the design of artificial organ devices and findings from initial testing. Bimonthly, the ASAIO Journal features state-of-the-art investigations, laboratory and clinical trials, and discussions and opinions from experts around the world. Also included are papers presented at the ASAIO annual meeting as well as diagrams, photographs, charts, and graphs.
About Lippincott Williams & Wilkins
Lippincott Williams & Wilkins (LWW) is a leading international publisher for healthcare professionals and students with nearly 300 periodicals and 1,500 books in more than 100 disciplines publishing under the LWW brand, as well as content-based sites and online corporate and customer services.
LWW is part of Wolters Kluwer Health, a leading provider of information and business intelligence for students, professionals and institutions in medicine, nursing, allied health and pharmacy. Major brands include traditional publishers of medical and drug reference tools and textbooks, such as Lippincott Williams & Wilkins and Facts & Comparisons®; and electronic information providers, such as Ovid®, UpToDate®, Medi-Span® and ProVation® Medical.
Wolters Kluwer Health is part of Wolters Kluwer, a market-leading global information services company. Professionals in the areas of legal, business, tax, accounting, finance, audit, risk, compliance, and healthcare rely on Wolters Kluwer’s leading, information-enabled tools and solutions to manage their business efficiently, deliver results to their clients, and succeed in an ever more dynamic world. Wolters Kluwer has 2009 annual revenues of €3.4 billion ($4.8 billion), employs approximately 19,300 people worldwide, and maintains operations in over 40 countries across Europe, North America, Asia Pacific, and Latin America. Wolters Kluwer is headquartered in Alphen aan den Rijn, the Netherlands. Its shares are quoted on Euronext Amsterdam (WKL) and are included in the AEX and Euronext 100 indices.
